McKesson, CD&R to Buy Option Care Health for $5.8 Billion

McKesson Corp. and private equity firm Clayton Dubilier & Rice agreed to buy Option Care Health Inc. for an enterprise value of about $5.8 billion, according to Bloomberg. The deal pairs the country's largest drug distributor with a buyout firm already active in health care, and it hands them a company that administers specialty medications to patients outside hospital walls.

The transaction, announced Oct. 6, lands at a moment when demand for infusion services is climbing alongside the rollout of specialty drugs for cancer and other serious conditions, Bloomberg reported. That demand is the stated rationale behind the price tag, which values Option Care Health at roughly $5.8 billion including debt.

What did McKesson and CD&R agree to buy?

Option Care Health provides home and alternate-site infusion services, administering drugs that would otherwise require a hospital visit. Bloomberg's reporting ties the acquisition directly to the growth of specialty pharmaceuticals — treatments for cancer and other conditions that increasingly require infusion rather than a pill or injection a patient can self-administer. McKesson, as a distributor, and CD&R, as a financial sponsor, are betting that the infrastructure Option Care Health has built to deliver those drugs will only become more valuable as the specialty-drug pipeline expands.

How much is the deal worth?

The enterprise value is about $5.8 billion, Bloomberg reported. Enterprise value typically accounts for a company's debt load alongside its equity value, giving a fuller picture of the total price a buyer is taking on than a simple stock-purchase figure would. Bloomberg's report did not break out a per-share price or detail how the consideration will be split between McKesson and CD&R, and neither company's own statement on deal terms was included in the available reporting.

Why are buyers targeting infusion services now?

The growth of specialty drugs for cancer and other conditions is driving demand for medical infusion services, according to Bloomberg's reporting on the deal. That single sentence carries the weight of the entire transaction's logic: as more complex biologic and specialty therapies reach approval, more of them require infusion — delivery through an IV rather than a pill bottle. A company that already runs the logistics, nursing staff, and sites of care for that kind of treatment becomes a strategic asset for a drug distributor looking to move beyond simply shipping product, and for a private equity firm looking for a health care platform tied to a growth trend rather than a cyclical one.

For McKesson specifically, the move extends its reach past the warehouse-and-truck model that defines traditional drug distribution. For CD&R, it adds another health care holding to a portfolio the firm has built over multiple cycles, though the specifics of that broader portfolio were not detailed in the sourced reporting and are not restated here.

What happens to Option Care Health next?

Bloomberg's report frames this as a definitive agreement to buy the company, meaning Option Care Health shareholders are expected to vote on the transaction and regulators will review it before any closing. The available reporting does not specify a target closing date, a termination fee, or whether the deal requires antitrust clearance beyond the standard process such transactions face. Those procedural details typically surface in a company's own securities filings once a deal of this size is formally announced, and HTT News will update this story as that documentation becomes public.

What to watch next

• Deal documentation. Watch for Option Care Health's securities filings, which should spell out per-share terms, financing structure, and the breakdown between McKesson's and CD&R's stakes.
• Regulatory review. A deal of this size in the health care supply chain typically draws antitrust scrutiny; watch for any request for additional information from federal regulators.
• Shareholder vote timing. Option Care Health investors will need to approve the transaction before it closes.
• Market reaction. Trading in Option Care Health shares and any analyst commentary on McKesson's strategy will signal how Wall Street is pricing the bet on specialty-drug infusion demand.

The deal's closing terms, financing details, and management commentary were not included in the sourced reporting as of publication. HTT News will follow the companies' formal statements and any regulatory filings as they become available.